DT News - UK - MRD provider ResMed expands in European markets

Search Dental Tribune

MRD provider ResMed expands in European markets

Narval CC offers efficacy and comfort for patients with mild to moderate OSA and snoring, among other indications. (Photograph: ResMed, France)

Wed. 6 July 2016

save

LONDON & SUNDERLAND, UK/LYON, France: The manufacturer of the Narval CC mandibular repositioning device (MRD), ResMed, has announced it is extending its services to ten countries in Europe, including the UK and Ireland. The new network will be built on partnerships involving accredited dental laboratory partners in each market and will allow clinicians to offer a faster and more personalised service to patients suffering from sleep apnoea, snoring and similar conditions.

According to the company, the decision to expand into local markets was due to the growing demand for its snoring and sleep apnoea device in Europe. Instead of sending dental impressions by mail to the company’s production centre in France, clinicians will now be able to submit them to a laboratory partner in their own country. The laboratory will prepare a model, scan it and send the data via the cloud to Lyon, where the MRD will be designed and then sent to the laboratory for quality control. This way, clinicians can benefit from a faster, more precise service in addition to working with a market leader in obstructive sleep apnoea (OSA) and trusted local partners, the company said.

“In recruiting and training laboratory partners in most European countries, we are better positioned to service the dental sleep physician whilst continuing to advance our digital workflow and continue to drive toward our goal to improve 20 million lives by 2020,” commented Ross Phillips, Commercial Director of Narval Europe.

A worldwide innovator in sleep-disordered breathing and respiratory care, ResMed introduced its custom-made MRD to dental markets in 2009. Originally developed in the US, Narval CC offers efficacy and comfort for patients with mild to moderate OSA and snoring, as well as those who are non-compliant with or for whom continuous positive airway pressure therapy has failed. Composed of an innovative polyamide material, the device is reported to be stronger, lighter and more durable than other MRDs on the market.

“OSA is a debilitating condition that can have serious consequences for patients and their partners. At ResMed, we are committed to helping patients live life to the fullest and have used the latest technological advancements to offer an effective, patient-focused innovation which offers greater comfort than ever before,” Philips said.

To post a reply please login or register
advertisement
advertisement